Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    ASAndrea SbonerJMJuan Miguel MosqueraOEOlivier ElementoHBHimisha Beltran
    PMID: 37223924PMCID: PMC10524949DOISenior author45 citations
  2. 2
    Journal of the National Cancer Institute · 2024
    ASAndrea SbonerHBHimisha Beltran
    PMID: 37676819PMCID: PMC10777679DOISenior author7 citations
  3. 3
    NPJ precision oncology · 2023
    FKFrancesca KhaniDJDavid J PisapiaBDBrian D. RobinsonJMJuan Miguel Mosquera+2 more →HBHimisha Beltran
    PMID: 37704749PMCID: PMC10499931DOISenior author11 citations

Publications

289 publications

Funding

24 grantsView NIH portfolio on RePORTER ↗

Active

4 grants
  • PI
    Career Enhancement Program
    NCI · 2023–2028 · via NIH RePORTER
    P50CA272390-04
  • MPI
    "DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
    NCI · 2023–2028 · via NIH RePORTER
    R01CA274963-04
  • Co-I
    Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation
    Prostate Cancer Foundation · 2017–2027
    17CHAL11
  • PI
    Molecular mechanisms underlying lineage plasticity in prostate cancer
    NCI · 2020–2027 · via NIH RePORTER
    R37CA241486-07
Completed grants (20)
  • Co-I
    Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer
    American Association for Cancer Research · 2017–2024 · via Sloan-Kettering Institute for Cancer Research
    SU2C-AACR-DT22-17
  • Co-I
    Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
    National Cancer Institute · 2017–2023
    P50CA211024-05
  • KP
    Personalized in vitro models to advance precision medicine
    National Cancer Institute · 2019–2023 · via Leidos Biomedical Research
    HHSN26100008
  • Co-I
    Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies
    U.S. Department of Defense · 2018–2022
    W81XWH-18-2-0032
  • Co-I
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2017–2022
    UL1TR002384-01
  • Co-I
    CENTER ON THE PHYSICS OF CANCER METABOLISM -Microfabrication Core 10802
    National Cancer Institute · 2016–2021 · via Cornell University - Ithaca
    U54CA210184-05
  • PI
    Temporal Evolution of N-Myc Signaling and Early Targeting of the Neuroendocrine Phenotype in Prostate Cancer
    U.S. Department of Defense · 2017–2020
    W81XWH-17-1-0653
  • Co-I
    Mechanistic Insights Underlying ERG-Induced Taxane Resistance in Castration-Resistant Prostate Cancer
    National Cancer Institute · 2014–2020
    R01CA179100-05
  • MPI
    DF/HCC SPORE in Prostate Cancer
    NCI · 2002–2019 · via NIH RePORTER
    P50CA090381-15
  • Co-I
    Identification of Antibody Therapeutics for Treatment of Neuroendocrine Prostate Cancer
    Janssen Research & Development, LLC · 2016–2019Contract
    Janssen RAA
  • KP
    Precision Medicine Sequencing
    Prostate Cancer Foundation · 2012–2019
    PCF 170814-EWOF
  • PI
    Impact of Therapy on Modulation of Neuroendocrine-Associated Gene Expression in Patients With High Risk, Localized Prostate Cancer Treated With Neoadjuvant Docetaxel and Androgen Deprivation Therapy
    Alliance for Clinical Trials in Oncology · 2015–2018
    ACT 15050798-02
  • PI
    Targeting BRN2 in Neuroendocrine Prostate Cancer
    Prostate Cancer Foundation · 2017–2018
    17CHAL13
  • PI
    Early Detection of Neuroendocrine Prostate Cancer Transformation Using Circulatin Genomic Signatures
    Prostate Cancer Foundation · 2014–2018
    PCF 15111792-02
  • Co-I
    Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies
    U.S. Department of Defense · 2014–2018
    W81XWH-14-2-0159 Yr
  • PI
    A Changing Landscape of Advanced Prostate Cancer: Understanding Mechanisms of Resistance to Potent Hormonal Therapies
    U.S. Department of Defense · 2013–2018Fellowship
    W81XWH-13-1-0275
  • PI
    Development and Qualification of the PCF SELECT (Specific Evaluation in Liquid Biopsies of Established Prostate Cancer Targets) Plasma DNA Assay
    Prostate Cancer Foundation · 2016–2018
    16CHAL01
  • Sub-PI
    Molecular Mechanics of Response to Combination Therapy in Early Lethal PCA
    National Cancer Institute · 2016–2018 · via The Brigham & Women's Hospital INC
    U10CA180821-04
  • KP
    Molecular Signatures of Lethal and Indolent Prostate Cancer
    National Cancer Institute · 2012–2017
    R01CA116337-09
  • KP
    Towards Understanding Prostate Cancer Heterogeneity
    National Cancer Institute · 2013–2017
    R01CA125612-09

Honors & distinctions

1 honor
  • Damon Runyon Fellowship / Grant · Damon Runyon Cancer Research Foundation · 2013